Showing results (1-10 of 41) with videos related to
Sort By:
Pageof 5
Current Oncology (Toronto, Ont.)|July 13, 2012
Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-lineN B LeighlCurrent Oncology (Toronto, Ont.)|June 19, 2018
Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trialsG M O'Kane, T A Barnes, N B LeighlCurrent Oncology (Toronto, Ont.)|July 13, 2012
Biomarkers that currently affect clinical practice: EGFR, ALK, MET, KRASM D Vincent, M S Kuruvilla, N B Leighl, et al.British Journal of Cancer|January 20, 2011
Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on studyN B Leighl, J Bennouna, J Yi, et al.Current Oncology (Toronto, Ont.)|April 25, 2015
Management of egfr tki-induced dermatologic adverse eventsB Melosky, N B Leighl, J Rothenstein, et al.Current Oncology (Toronto, Ont.)|June 23, 2016
Approach to biomarker testing: perspectives from various specialtiesM R Sung, P M Ellis, S Verma, et al.Current Oncology (Toronto, Ont.)|June 19, 2014
Access to personalized medicine: factors influencing the use and value of gene expression profiling in breast cancer treatmentY Bombard, L Rozmovits, M Trudeau, et al.British Journal of Cancer|June 10, 2011
Biomarkers of clinical benefit for anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancerA G Pallis, D A Fennell, E Szutowicz, et al.Current Oncology (Toronto, Ont.)|April 26, 2014
Patients' perceptions of gene expression profiling in breast cancer treatment decisionsY Bombard, L Rozmovits, M E Trudeau, et al.Current Oncology (Toronto, Ont.)|November 23, 2018
Afatinib in advanced pretreated non-small-cell lung cancer- a Canadian experienceD A Ezeife, B Melosky, R Tudor, et al.Pageof 5